Trevi Therapeutics, Inc.
NASDAQTrevi Therapeutics enters the final stretch before its June 3 catalysts with a sharp 10.3% weekly decline creating a notable tension: every analyst still rates the stock a buy, yet the market has pulled it down 13% in a month. The most striking feature of this week's setup is the options market. Call dominance is extreme — the put/call ratio has collapsed to 0.18, nearly two…
Snapshot as of 22 Jun 2026
Trevi Therapeutics enters the final stretch before its June 3 catalysts with a sharp 10.3% weekly decline creating a notable tension: every analyst still rates the stock a buy, yet the market has pulled it down 13% in…
Trevi Therapeutics enters its May 7 earnings release with a meaningful short base still in place, even as the stock has rebounded sharply and the lending market suggests bears are not pressing harder. Short sellers…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TRVI — free to start on ORTEX.
Sign up for free →Open TRVI on ORTEX